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Dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase (PDK), has been recently demonstrated as a promising
nontoxic antineoplastic agent that promotes apoptosis of cancer cells. In the present study, we aimed to investigate the antitumor
eﬀect of DCA combined with 5-Fluorouracil (5-FU) on colorectal cancer (CRC) cells. Four human CRC cell lines were treated
with DCA or 5-FU, or a combination of DCA and 5-FU. The cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assay. The interaction between DCA and 5-FU was evaluated by the median eﬀect principle.
Immunocytochemistrywithbromodeoxyuridine(BrdU)wascarriedouttodeterminetheproliferationofCRC cells.Cell cycleand
apoptosis were measured by ﬂow cytometry, and the expression of apoptosis-related molecules was assessed by western blot. Our
results demonstratedthatDCAinhibited theviabilityofCRC cells andhadsynergisticantiproliferationincombinationwith5-FU.
Moreover, compared with 5-FU alone, the apoptosis of CRC cells treated with DCA and 5-FU was enhanced and demonstrated
with the changes of Bcl-2, Bax, and caspase-3 proteins. Our results suggest that DCA has a synergistic antitumor eﬀect with 5-FU
on CRC cell lines in vitro.
1.Introduction
Colorectal cancer is one of the most common malignancies
worldwide [1]. Other than surgery, treatment for CRC
patients relies primarily on chemotherapy, especially the
patients with advanced CRC. Among the chemotherapeutic
agents for CRC, 5-Fluorouracil (5-FU), which is a classical
chemotherapy agent, has been the ﬁrst line regimen for
treating CRC over several decades [2, 3]. However, 5-FU
alone is poorly selective to tumor as well as highly toxic to
bone marrow, gastrointestinal tract, and skin when used at
the therapeutic dose [4].
Metabolic abnormity is one of critical hallmarks of can-
cer [5]. As early as 1920s, Otto Warburg observed that
cancer cells generally use glycolysis rather than oxidative
phosphorylation for energy [6]. Thus, the metabolic switch
to anaerobic respiration through glycolysis from pyru-
vate, rather than pyruvate conversion to acetyl-CoA by
action of pyruvate dehydrogenase (PDH) in aerobic glucose
metabolism, becomes a preferential phenotype of cancer
progress. PDHcan beinactivated by pyruvate dehydrogenase
kinase (PDK) in many glycolytic phenotypes including
cancer, while inhibition of PDK switches metabolism to
aerobic oxidation which is proved to be disadvantageous to
tumor growth [7].
Dichloroacetate (DCA) is a prototypical inhibitor of
mitochondrial PDK.Byblockingtheenzyme, DCAdecreases
lactate production by shifting the metabolism of pyruvate
from glycolysis towards oxidation in the mitochondria. This
property has led to trials of DCA for the treatment of
lactic acid accumulation disorders [8]. Recently, studies
have demonstrated that DCA suppresses tumor growth via
inhibition of PDK [9–11]. Michelakis and his colleagues
found that DCA restored mitochondrial function, thus
restoringapoptosis,killingcancercellsinvitro,andshrinking
the tumors in the rats [12].
Combination chemotherapy has been used widely. 5-FU
is usually combined with other antineoplastic agents and
radiation to enhance its antitumor eﬀect. The clinical
insuﬃciency appears to be caused from resistance of 5-FU2 Journal of Biomedicine and Biotechnology
a n ds e v e r es i d ee ﬀects. The strong and selective induction
of apoptosis suggests that the PDK inhibitor DCA may
potentiate the inhibitory eﬀect of anticancer drugs, thus
exceedingtheeﬃcacyofcurrenttreatment.Herein,weaimed
to examine the combined antitumor eﬀects of DCA with
5-FU on the CRC cells, in hoping of assessing a relatively
eﬀective and safe regimen potentiated for CRC treatment.
2.MaterialandMethods
2.1. Cells and Regents. The human colon cancer cell lines
LS174T, LoVo, SW620, and HT29 were purchased from
American Type Culture Collection (Manassas, VA, USA).
Cell culture reagents were purchased from Gibco-Invitrogen
(Carlsbad, CA, USA). Cell lines were maintained in Dul-
becco’s Modiﬁed Eagle’s medium or Leibovitz L-15 medium
containing 10% fetal bovine serum (FBS), 100U/mL peni-
cillin, and 100μg/mL streptomycin in a 37◦C, 5% CO2
humidiﬁed incubator. 5-FU and DCA was purchased from
Sigma-Aldrich Co. ltd. (St. Louis, MO, USA), dissolved in
deionized water to make 1mol/L working solution, ﬁlter-
sterilized, and subsequently diluted in growth medium for
treatment.
2.2. Cell Viability Assay. Cell viability was determined us-
ing the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide (MTT) assay (Sigma-Aldrich). Cells were
seeded into 96-well plates (5 × 104 cells per well) and
incubated under standard growth conditions overnight from
60% to 70% conﬂuence. Cells were then treated with DCA
alone(ﬁnalconcentration0–90mM)orwithDCAcombined
with 5-FU (5–200μM). After a 48-hour treatment, cells were
incubated at 37◦C for another 4hours with MTT (20μLp e r
well) and the absorbance at 490nm was measured in a Bio-
Rad Model 550 plate reader (Hercules, CA, USA).
2.3. Analysis of Drug Interaction. The interaction between
DCA and 5-FU was analyzed by using the median eﬀect
principle described by Chou and Talalay [13, 14]. The
program enables calculation of combination indices (CIs)
which, when smaller than 1, equal to 1, or greater than 1,
indicate synergism, additivity, or antagonism, respectively,








where (Dx)1 and (Dx)2 are the concentrations of DCA alone
or 5-FU alone, giving x% growth inhibition, and (D)1 and
(D)2 are the drug concentrations in combination inhibiting








where Dm is the median-eﬀect dose, fa is the fraction
aﬀected,andmrepresentstheslopeofthemedian-eﬀectplot.
2.4. Cell Proliferation Assays. Immunocytochemistry was
carriedoutwithbromodeoxyuridine(BrdU)(BDBioscience,
San Jose, CA, USA) in vitro. Cells were propagated on cov-
erslips in 12-well plates under standard growth conditions.
After 24hours, various concentrations of DCA, 5-FU, or a
combination of two drugs were added. Cells were serum-
starved for 12hours in growth media containing 0.5% FBS
to reset the cell cycle to G0 phase, and then cells were
pulsed for 2hours with 10μmol/L BrdU in growth media.
Subsequently, the cells were ﬁxed, washed, and stained
according to the manufacturer’s instruction.
Cell cycle analysis was determined indirectly using pro-
pidium iodine (PI, BD Bioscience) staining by ﬂow cytome-
try (FACScan, Becton Dickinson, San Jose, CA, USA). Cells
were seeded into 6-well plates and cultured with or without
10mM DCA or 20μM 5-FU. After incubating for 48hours,
cells were harvested with 0.25% Trypsin-EDTA (Invitrogen,
Carlsbad, CA, USA).Then, cells were ﬁxed with 70% alcohol
for 24hours at 4◦C and washed twice with phosphate buﬀer
saline (PBS). RNAase (100μL; 1mg/mL) (BD Bioscience)
was added, and cells were incubated in a 37◦Cw a t e rb a t hf o r
30minutes. After staining with 200μLP I( 5 0 μg/mL), cells
were held at 4◦C for 30minutes. Finally, cells were analyzed
by ﬂow cytometry.
2.5.ApoptosisAssay. Apoptosiswas detectedbyﬂowcytome-
try with annexin-V-FITC (BD Bioscience) and PI. Cells were
seeded into 6-well plates. After a 48-hour incubation with or
without drugs, cells were washed and resuspended in 0.5mL
PBS buﬀer. After staining with annexin-V-FITC and PI,
cells were analyzed by ﬂow cytometry in three independent
experiments.
2.6. Western Blot. Cells were harvested and total pro-
teins were extracted with RIPA buﬀer containing protease
inhibitors. Total protein (50μg) was subjected to 10% or
12% SDS/PAGE, and the resolved proteins were transferred
electrophoretically to PVDF membranes (Millipore, Bed-
ford, MA, USA). Membranes were blocked for 2hours with
5% nonfat milk in TBS buﬀer containing 0.05% Tween-
20 (TBST) at 4◦C. Membranes were then incubated with
antibodies to Bax, Bcl-2, Caspase-3, and GADPH overnight
at 4◦C. After washing in TBST, the membranes were incu-
bated with their respective secondary antibodies for 1hour.
Membranes were then incubated with SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL,
USA) for 1minute and imaged using a Gel Doc XR system
(Bio-Rad). All of the antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
2.7. Statistics. All data are expressed as means ± standard
deviation (SD). Statistical analysis was performed using the
SPSS 13.0 software (SPSS, Chicago, IL, USA). Diﬀerences
between two groups were determined by paired-samples t-
test or independent-samples t-test (two-tailed) as indicated.
Diﬀerencesamong groupswereanalyzed byone-way analysis
of variance (ANOVA). P<. 05 was considered statistically
signiﬁcant.Journal of Biomedicine and Biotechnology 3
3.Results
3.1. Viability of CRC Cells Treated with DCA Alone or in
Combination with 5-FU. To determine the eﬀect of DCA
on CRC cells, cells were exposed to DCA (0–90mM) for
48hours. The result showed that inhibitory eﬀect was
dose dependent. As shown in Figure 1, the inhibition of
viability of cancer cell lines treated with 50mM DCA was
as follows: SW620 (46.73% ± 5.21%), LoVo (30.94% ±
3.57%), LS174t (54.59% ± 3.93%), and HT29 (55.31% ±
3.35%). We treated cells with 5-FU (20–100μM) and found
that the viability of SW620, LoVo, LS174t was inhibited
signiﬁcantly except HT29, with its viability inhibition not
obvious under 80μM 5-FU. When treated with these two
drugs simultaneously, the viability of aforementioned CRC
cells was signiﬁcantly decreased compared with DCA or 5-
FU alone (IC50 values are shown in Table 1).
3.2. Synergistic Eﬀects of DCA Combined with 5-FU in CRC
Cell Lines. The viability of CRC cells were decreased in the
presence of 5-FU and DCA. DCA potentiated the inhibitory
eﬀects of 5-FU on CRC cells, and the inﬂuence of DCA on
eﬀects of 5-FU was dose dependent (Figure 1). Interaction
between 5-FU and DCA was analyzed with median eﬀects
method. The combination of DCA and 5-FU produced
synergistic or additive eﬀects depending on the range of cell
kill level (Fa). All of four CRC cell lines indicated synergistic
eﬀect with 5-FU and DCA. The synergism was statistically
signiﬁcant in LS174t at inhibition levels of 50% and 80%,
achieving CI values from 0.46–0.61, and in HT-29 cell line at
inhibition levels of 50 and 80%, with CI values in the range
from 0.42 to 0.52. In SW620 and LoVo cells, CI values at
50%and80%inhibitionlevelswere0.64–0.75and0.75–0.94,
respectively, (Figure 2).
3.3. DCA Increased the Eﬃciency of Antiproliferative Eﬀect
of 5-FU. To conﬁrm that decreased cell viability was due
to reduced proliferation, immunocytochemistry, and ﬂow
cytometry were employed. Cells were treated with 10mM
DCA combined with 20μM 5-FU. As expected, cells treated
with DCA demonstrated reduced proliferation compared
with untreated cells. The number of BrdU positive cells on
four CRC cell lines after treatment with 5-FU and DCA were
11.4 ± 2.12, 13.55 ± 3.10, 12.84 ± 1.34, and 18.83 ± 1.45,
respectively, which were lower than that treated with 5-FU
or DCA alone (P<. 01, see Table 2). In addition, treatment
with DCApotentiated the cell cyclearrest in G1 phase. When
treated with DCAand 5-FU, cellsblockedin G1/Sphase were
more than that of incorporated with DCA or 5-FU alone
(Figure 3).
3.4.Increased ApoptosisInduced byDCACombined with5-FU
in CRC Cells. To further investigate thedecreased viability of
CRC cells treated with combination regimen, apoptosis was
determined by ﬂow cytometry. As shown in Figure 4,D C A
aloneincreased theproportion ofapoptosisCRCcells. When
treated with 10mM DCA, the apoptosis rates of four CRC
cell lines were 15.72 ± 1.63%, 11.32 ± 0.74%, 9.77 ± 0.53%,
and 14.52 ± 1.00%, respectively, while the apoptosis rates
Table 1:IC50 values(concentrationsrequired toreduce theviability
of cells by 50% as compared with the control cells) were computed
using linear or nonlinear regression (three parametric Hill func-
tion) (R2 > 0.9). They are presented as mean ± SD from at least
three independent experiments. IC50 values of the studied drugs for




SW620 LoVo LS174t HT29
5-FU
(μM) 99.50±2.31 127.23 ±1.28 177.45 ±2.16 798.38± 1.25
DCA
(mM) 37.65±1.03 29.15 ±0.93 56.97 ±0.84 47.02± 0.52
Table 2:SW620,LoVo,LS174t,HT29cells,and293Tnoncancerous
controls were treated with 10mM DCA and 20μM5 - F Ua l o n e
or in combination for 48hours, and then pulsed with BrdU. Cells
were then harvested and stained, and the numbers of BrdU+
cells were calculated as the mean number of the positive cells in
eight diﬀerent ﬁelds of view in one image (magniﬁcation, 400X).
This calculation was repeated three times. ∗P<. 05, compared
with control. BrdU+ cells in diﬀerent drug treatment (%, mean ±
SD).
Drugs BrdU+ rate
SW620 LoVo LS174t HT29
untreated 39.70 ±2.13 40.54 ± 1.28 38.53 ±0.94 42.14 ±3.18
5-FU 25.2 ±2.40 27.33 ± 1.47 27.94 ±0.83 40.53 ±2.71
DCA 30.4 ±1.25 28.25 ± 2.17 31.72 ±0.73 29.94 ±2.16
5-FU+DCA 11.4 ±2.12 13.55 ± 3.10 12.84 ±1.34 18.83 ±1.45
were 9.14 ± 119%, 8.82 ± 0.41%, 10.31 ± 0.71%, and 7.27
± 0.96% with 5-FU. When combination of DCA and 5-FU
was applied, the apoptosis rate was much higher than 5-FU
orDCAalone(P<. 05),which indicatedapoptoticeﬀectwas
increased via combination DCA and 5-FU (Figure 4).
3.5. Changes on Apoptosis-Associated Molecules Stimulated by
DCAand5-FU. Toconﬁrmthatincreasedapoptosisinduced
by combination therapy was due to modiﬁed expressions
of apoptosis-associated molecules, western blot assay was
applied. In Figure 5, the results indicated that 5-FU or DCA
decreased the expression of Bcl-2 in four CRC cell lines
compared to PBS controls, and the combination ofDCAand
5-FU decreased Bcl-2 expression signiﬁcantly as compared
with DCA or 5-FU alone. Conversely, the expressions of
Bax and caspase-3 were signiﬁcantly increased in the four
CRC cell lines treated with combination of DCA and 5-FU
compared to their single usage. The most obvious increasing
of Bax expression was detected in LS174t cells, while in
LoVo it appeared that caspase-3 expression increased most
(Figure 5).
4.Discussion
In the present study, we demonstrate that DCA not only
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Figure 1: Viability of four CRC cell lines in response to treatment with dichloroacetate (DCA) and 5-ﬂuorouracil (5-FU). The viability of
SW620, LoVo, LS174t, and HT29 was decreased signiﬁcantly with diﬀerent concentration of 5-FU and DCA alone or in combination. Each
experiment was performed in triplicate; ∗P<. 05.
the synergistic antitumor eﬃciency with chemotherapeutic
agent 5-FU in vitro in CRC cells. Meanwhile, DCA has
no signiﬁcant eﬀects on noncancerous cells. Furthermore,
we showed that DCA-induced apoptosis contributes to its
synergistic antitumor eﬀect. Compared with DCA or 5-
FU alone, combination usage of these two drugs promotes
apoptosis of CRC cells.
5-FU is a chemotherapy drug used to treat several types
of cancer, including colorectal, breast, esophageal, and stom-
ach [15]. However, 5-FU–related toxicity is a serious and
commonissue for many cancer patients, with myelosuppres-
sion and gastrointestinal toxicity being the most commonly
observed side eﬀects [16]. The clinical activity of 5-FU is
modest at standard doses, and in general, dosing is limited
by the safety proﬁle. As a result, we are usually left with
the dilemma of making decisions about the therapeutic dose
of 5-FU. Various strategies have been developed to enhance
the clinical activity of 5-FU, such as biochemical modulation
[17], alterations in scheduling of administration [18], and
the use of combination therapy [19–22].
DCA is an odorless, colorless, inexpensive, relatively
nontoxic, small molecule. It has been in clinical use since
1969 for treatment of lactic acidosis via boosting the ability
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Figure 2: Mean values of the combination index at the aﬀected
fractions of 50% (IC50) and 80% (IC80) when 5-ﬂuoruracil (5-FU)
wascombinedwithdichloroacetate (DCA) inHT-29,LoVo,LS174t,
and SW620 cells. Mean IC50 and IC80 ± SD (n = 3) are shown.
A CI value signiﬁcantly less than 1 indicates synergism, a CI not
signiﬁcantly diﬀerent from 1 indicates addition, and a CI signiﬁ-




















































































































Figure 3: Changes in cell cycle progression in SW620, LoVo,
LS174t, and HT29 cells after 48-hour treatment with 5-ﬂuoruracil
(5-FU) and dichloroacetate (DCA) applied alone or in combina-
tion.Each bar represents the mean ±SD(n = 3).Thedata obtained
from FACS were analyzed using SPSS13.0; ∗P<. 05.
accumulation [23]. DCA has been considered as a potential
cancertherapy regimen since a Canadian group found that it
caused regression in several cancers, including lung, breast,
and brain tumors [24, 25]. When given to cancer cells,
the cells switched from glycolysis to mitochondrial energy
production.What’smore, functional mitochondria help cells
recognize functional abnormalities and trigger cell death
due to its inhibition of tumor growth and induction of
apoptosis in certain cancer. In the present study, we found
the same viability inhibitory eﬀect in CRCs, which was
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Figure 4: Induction of apoptosis in SW620, LoVo, LS174t, and
HT29 cells after 48-hour treatment with 5-ﬂuoruracil (5-FU)
and dichloroacetate (DCA) alone or in combination. Each bar
represents the mean ± SD (n = 3); ∗P<. 05.
diﬀerentiation. The results also indicated that low-dose DCA
exerts a synergistic eﬀect with chemotherapeutic agent 5-
FU in halting growth of CRC cells, which was quantitatively
analyzed according to Chou-Talalay method.
The results of cell proliferation also demonstrated that
DCA enhanced the antiproliferational eﬀects of 5-FU. The
number of BrdU positive cells was decreased when treated
with 5-FU or DCA, while the BrdU-stained cells were
decreased signiﬁcantly when treated with combination of 5-
FU and DCA compared with their single usage. Meanwhile,
the growth inhibition of CRC cell was accompanied by cell
cycle arrest. Combination of DCA and 5-FU induced cell
cycle arrest in G1/S phase in CRC cell lines, whereas 5-FU
induced arrest in G1 phase was not obvious. The induction
of cell cycle arrest may result from inhibitory ability to
synthesize or repair DNA, which may lead to cell apoptosis.
DCA appeared to exert biochemical eﬀects consistent
with reversing the Warburg eﬀect and killing cancer cells.
We found that DCA-induced CRC cells apoptosis, which is
orchestrated with the previous DCA studies. Importantly,
the combination of DCA with 5-FU increased the number
of apoptotic cells compared with 5-FU alone, demonstrating
that DCA inhibited cell growth via apoptosis.
Many factors mediating apoptosis converge to activate
the critical eﬀector the caspase-3, which is considered as the
key protease of caspase family in mammalian cell apoptosis
[26]. It always exists as a 23kD inactive precursor in
cytoplasm, which is activated during apoptosis and takes
part in apoptosis induced by multiple factors. Caspase-
dependent apoptosis pathway mainly includes mitochondria
pathway,deathreceptorpathway,andendoplasmicreticulum
pathway [27]. And the mitochondria pathway is controlled
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Figure 5: Eﬀects of 5-ﬂuorouracil (5-FU) and dichloroacetate (DCA) on apoptosis-associated molecules expression. Bcl-2 expression was
signiﬁcantlydecreased by DCA in SW620,LoVo, and LS174tand HT29 cells. Bax and caspase-3 expression levels were higher after exposure
to 5-FU and DCA compared with control.
which are divided into two parts, the antiapoptotic members
(Bcl-2) and proapoptotic members (Bax) [30]. Recent study
indicates that the Bcl-2 inhibits apoptosis via inhibiting
Bax removing to mitochondrial outer membrane [31]. We
investigated the expression of caspase-3, Bcl-2, and Bax in
protein level and the result of western blot showed that the
expressions of caspase-3 and Bax were increased, while the
expression of Bcl-2 was decreased in the combination of
DCA with 5-FU treatment, comparing with the single treat-
ments. These results suggested that the apoptosis induced by
the combination of DCA and 5-FU might be related with
caspase-dependent mitochondria pathway. Previous investi-
gations suggested that the induction of apoptosis by DCA
resulted from returning the dysfunction of the mitochondria
and NFAT-Kv1.5 pathway [9, 12], which focused on the
same point aspresent study thatwas mitochondria-mediated
apoptosis.
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